[Article] A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide

Moiseev I, Drokov M, Kitaeva Y, Rudakova T, Barabanshchikova M, Chernyshova D, Bondarenko S, Kuzmina L, Rodionov G, Svetkina E, Lapin S, Kholopova I, Morozova E, Vasilyeva V, Vlasova Y, Zhogolev D, Konstantinova T, Parovichnikova E, Kulagin A. A randomized, multicenter phase II trial to compare prophylaxis of graft versus host disease with tacrolimus and mycophenolate mofetil versus ruxolitinib after post-transplant cyclophosphamide. Transplant Cell Ther. 2026 Sep;32(9):1117.e1-1117.e11.

doi: 10.1016/j.jtct.2026.04.042. Epub 2026 Apr 30. PMID: 42066960.

url: https://www.sciencedirect.com/science/article/abs/pii/S2666636726003337?via%3Dihub